Skip to main content

Table 2 Characteristics of the patients aged 70 years or older, overall cohort and propensity-matched cohort

From: The efficacy of adjuvant chemotherapy for older adults with stage II/III gastric cancer: a retrospective cohort study

 

Overall cohort

Propensity-matched cohort

No

chemotherapy

(n = 70)

Adjuvant

chemotherapy

(n = 109)

P-value

SMD

No

chemotherapy

(n = 50)

Adjuvant chemotherapy

(n = 50)

P-value

SMD

Age, median (IQR)

81.5

(76.75-85)

77

(73–81)

< 0.001

0.663

79.5

(75–84)

79.5

(75–83)

0.920

0.004

Sex, n (%)

    

0.620

0.076

    

0.509

0.133

Female

23

(32.9%)

32

(29.4%)

  

16

(32.0%)

13

(26.0%)

  

Male

47

(67.1%)

77

(70.6%)

  

34

(68.0%)

37

(74.0%)

  

BMI, n/total n (%)

    

0.945

0.051

    

1.000

< 0.001

< 18.5

6/69

(8.7%)

8/108

(7.4%)

  

3/49

(6.1%)

3/49

(6.1%)

  

18.5–23.9

34/69

(49.3%)

55/108

(50.9%)

  

23/49

(46.9%)

23/49

(46.9%)

  

≥ 24.0

29/69

(42.0%)

45/108

(41.7%)

  

23/49

(46.9%)

23/49

(46.9%)

  

ECOG performance status, n (%)

    

< 0.001

0.680

    

0.839

0.041

0–1

20

(28.6%)

66

(60.6%)

  

20

(40.0%)

21

(42.0%)

  

2–4

50

(71.4%)

43

(39.4%)

  

30

(60.0%)

29

(58.0%)

  

aCCI, n (%)

    

0.015

0.392

    

0.603

0.104

0–3

9

(12.9%)

31

(28.4%)

  

8

(16.0%)

10

(20.0%)

  

≥ 4

61

(87.1%)

78

(71.6%)

  

42

(84.0%)

40

(80.0%)

  

Year of diagnosis, n (%)

    

0.255

0.175

    

1.000

< 0.001

2009–2013

37

(52.9%)

67

(61.5%)

  

30

(60.0%)

30

(60.0%)

  

2014–2017

33

(47.1%)

42

(38.5%)

  

20

(40.0%)

20

(40.0%)

  

Histologic grade, n (%)

    

0.180

0.202

    

0.444

0.153

well to moderate

15

(21.4%)

15

(13.8%)

  

11

(22.0%)

8

(16.0%)

  

poor differentiation

55

(78.6%)

94

(86.2%)

  

39

(78.0%)

42

(84.0%)

  

Signet-ring feature, n/total n (%)

    

0.682

0.063

    

0.599

0.106

No

55

(78.6%)

82/108

(75.9%)

  

39

(78.0%)

36

(73.5%)

  

Yes

15

(21.4%)

26/108

(24.1%)

  

11

(22.0%)

13

(26.5%)

  

Gastrectomy type, n (%)

    

0.447

0.116

    

0.838

0.041

Subtotal gastrectomy

41

(58.6%)

70

(64.2%)

  

31

(62.0%)

30

(60.0%)

  

Total gastrectomy

29

(41.4%)

39

(35.8%)

  

19

(38.0%)

20

(40.0%)

  

Lymphadenectomy type, n (%)

    

0.036

0.322

    

0.838

0.041

< D2 dissection

32

(45.7%)

33

(30.3%)

  

19

(38.0%)

30

(60.0%)

  

D2 dissection

38

(54.3%)

76

(69.7%)

  

31

(62.0%)

20

(40.0%)

  

Stage, n (%)

    

0.069

0.281

    

1.000

< 0.001

Stage II

36

(51.4%)

41

(37.6%)

  

22

(44.0%)

22

(44.0%)

  

Stage III

34

(48.6%)

68

(62.4%)

  

28

(56.0%)

28

(56.0%)

  

Lymphovascular invasion, n/total n (%)

    

0.056

0.290

    

1.000

< 0.001

No

23

(32.9%)

22

(20.2%)

  

13

(26.0%)

13

(26.0%)

  

Yes

47

(67.1%)

87

(79.8%)

  

37

(74.0%)

37

(74.0%)

  

Perineural invasion, n/total n (%)

    

0.463

0.113

    

0.841

0.040

No

36/70

(51.4%)

49/107

(45.8%)

  

25

(50.0%)

26

(52.0%)

  

Yes

34/70

(48.6%)

58/107

(54.2%)

  

25

(50.0%)

24

(48.0%)

  

CEA level, n/total n (%)

    

0.837

0.033

    

0.615

0.104

Normal

53/64

(82.8%)

84/103

(81.6%)

  

39/46

(84.8%)

38/47

(80.9%)

  

Elevated (≥ 5 U/ml)

11/64

(17.2%)

19/103

(18.4%)

  

7/46

(15.2%)

9/47

(19.1%)

  

CA 19 − 9 level, n/total n (%)

    

0.832

0.037

    

0.473

0.106

Normal

41/51

(80.4%)

71/90

(78.9%)

  

31/38

(81.6%)

33/44

(75.0)

  

Elevated (≥ 34 U/ml)

10/51

(19.6%)

19/90

(21.1%)

  

7/38

(18.4%)

11/44

(25.0)

  

NLR, n/total n (%)

    

0.467

0.112

    

0.841

0.040

≤ 2.6

32/70

(45.7%)

43/107

(40.2%)

  

23

(46.0%)

22

(44.0%)

  

> 2.6

38/70

(54.3%)

64/107

(59.8%)

  

27

(54.0%)

28

(56.0%)

  

PLR, n/total n (%)

    

0.906

0.018

    

0.689

0.080

≤ 166

34/70

(48.6%)

51/107

(47.7%)

  

24

(48.0%)

26

(52.0%)

  

> 166

36/70

(51.4%)

56/107

(52.3%)

  

26

(52.0%)

24

(48.0%)

  
  1. aCCI, age-adjusted Charlson comorbidity index; BMI, body mass index; CA 19 − 9, carbohydrate antigen 19 − 9; CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; SMD, standardized mean differences
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us